SF3B1 and B-cell chronic lymphocytic leukemia: In conclusion, we reinforce SF3B1 mutations as a key biomarker with a very strong negative impact on TTFT in both M-CLL and U-CLL and also highlight XPO1 as an additional highly relevant gene in both subgroups.